July 14, 2009-Philadelphia, PA
American College of Radiology (ACR) Image Metrix works closely with the American College of Radiology Imaging Network (ACRIN) to conduct Positron Emission Tomography (PET) trials. The PET core laboratory of ACRIN qualifies sites to participate in multicenter research trials by reviewing the quantitative data of PET scans and qualitatively reviewing clinical PET images from each site.
In a recent paper published by the Journal of Nuclear Medicine (July 12, 2009) , of 101 detailed scanner applications, 12% failed because of incorrect standardized uptake value (SUV) or normalization calibrations. Minimizing errors in SUV measurement is critical to achieving accurate quantification in clinical trials. ACRIN’s PET core laboratory shows that many sites are unable to maintain accurate SUV calibrations without additional training or supervision.
“The emerging role of PET imaging endpoints as in vivo biomarkers requires imaging studies to produce reliable quantitative, semi-quantitative and qualitative results that can be used to assess disease status. Ensuring such consistency in multi-center clinical trials that involve imaging is problematic. The problem stems from the fact that the data acquisition and reconstruction are performed in many different settings and often with different types of instrumentation. As described in our most recent peer reviewed publication, ACRIN has managed to develop a robust system to streamline data collection, data management and processing. Such system is paving the way for a better integration of molecular imaging in drug discovery processes,” stated Deputy Co-chair and Medical Director, PET Core Laboratory, ACRIN, Barry A. Siegel, MD.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.